Reclast (zoledronic acid) clears from your bloodstream within a few days, but it stays embedded in your bones for years. A single 5 mg infusion can maintain its effects on bone density for up to 10 years, making it one of the longest-acting osteoporosis medications available. This dual timeline, fast clearance from blood but prolonged storage in bone, is what most people find confusing, so it helps to look at each phase separately.
How Quickly Reclast Leaves Your Blood
After your infusion ends, Reclast levels in the blood drop fast. Within 24 hours, plasma concentrations fall to less than 1% of their peak. The drug’s terminal elimination half-life in blood is about 146 hours (roughly six days), but practically speaking, only trace amounts remain in circulation after the first two days. About 39% of the dose is flushed out through the kidneys in the first 24 hours alone, with very little appearing in urine after day two.
The rest of the dose doesn’t just disappear. It migrates to your skeleton, where it binds tightly to bone mineral.
Why Reclast Stays in Bone for Years
Reclast belongs to a class of drugs called bisphosphonates, which work by attaching to a mineral in bone called hydroxyapatite. Zoledronic acid has a particularly strong binding affinity for this mineral compared to other bisphosphonates. Once locked onto the bone surface, the drug sits there until the bone naturally remodels, a process where old bone is broken down and replaced. Because bone turnover is slow, and because Reclast itself slows that turnover further, the drug gets released from bone tissue very gradually over many years.
There is no single agreed-upon number for the “bone half-life” of Reclast, but clinical studies give a clear picture of the timeline. In a study of older postmenopausal women, a single 5 mg dose maintained bone mineral density at or above baseline levels at the spine for 9 years and at the hip for 10 years. Bone turnover markers, which reflect how actively the drug is suppressing bone breakdown, remain measurably reduced for at least 3 years after the last infusion. That residual suppression is longer than what’s seen with other bisphosphonates like risedronate, where the effect fades within about a year of stopping.
What This Means for Your Treatment Schedule
Because Reclast persists in bone so long, many people don’t need to stay on it indefinitely. After a period of treatment (typically 3 to 6 years of annual infusions), your doctor may suggest a “drug holiday,” a planned pause where you stop receiving infusions but still benefit from the drug already stored in your bones. A 2024 position statement from the American Society for Bone and Mineral Research notes that medication pauses should generally only be considered when bisphosphonates are the last treatment used, precisely because their residual effects persist for years. Other osteoporosis drugs lose their protective effect much more quickly after stopping.
The decision to take a holiday depends on your fracture risk, your bone density results, and how long you’ve been treated. Bone loss after stopping Reclast is significantly slower than bone loss after stopping other osteoporosis medications, which gives a meaningful cushion of protection during the pause.
Risks Linked to Long Bone Retention
The flip side of Reclast’s persistence is that its rare side effects are also tied to duration of exposure. Two complications get the most attention: atypical femur fractures and osteonecrosis of the jaw.
Atypical femur fractures are unusual breaks in the thighbone that occur with minimal trauma. They’re thought to happen because prolonged bisphosphonate exposure impairs the body’s ability to repair tiny stress injuries (microcracks) that accumulate in bone over time. A large nationwide study found the risk rises substantially with duration of use. After four or more years of bisphosphonate treatment, the relative risk of atypical fracture reached 126 times that of non-users. In absolute terms, that translates to about 11 fractures per 10,000 people per year of use, so it remains uncommon even at its peak.
Importantly, this risk drops quickly once you stop. It decreases by about 70% for each year since the last dose. Researchers believe this is because once new drug is no longer being deposited at microcrack sites, the body can resume normal repair at those locations even while older drug remains elsewhere in the skeleton. This rapid decline in risk after stopping is one of the strongest arguments for drug holidays in people who’ve been on bisphosphonates for several years.
Osteonecrosis of the jaw, where a section of jawbone fails to heal properly, is also linked to long-term bisphosphonate use but is very rare at the doses used for osteoporosis. It occurs more often in cancer patients receiving much higher and more frequent doses.
The Short Answer
Reclast is essentially gone from your bloodstream within two days. In your bones, a single dose exerts measurable effects for roughly a decade. Bone turnover stays suppressed for at least three years after your last infusion, and bone density can remain above pre-treatment levels for up to 10 years. This long persistence is why Reclast is dosed only once a year during active treatment and why planned treatment pauses are possible without immediately losing the bone protection you’ve built up.